Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models

Human Molecular Genetics

Volumn 18, Issue 6, 2009, Pages 1006-1016

  Phan, Jack ^a,c   Hickey, Miriam A ^a   Zhang, Peixiang ^a   Chesselet, Marie Francoise ^a,b   Reue, Karen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ADIPOCYTOKINE; ADIPONECTIN; CYTOSINE; GUANINE; HUNTINGTIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; FOOD INTAKE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GLUCOSE METABOLISM; HUNTINGTON CHOREA; KNOCKOUT MOUSE; LIPIDOSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCK-IN TECHNIQUES; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MUTATION; ORGAN SIZE; ORGAN SPECIFICITY; PPAR GAMMA; RESPONSE ELEMENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRANS-ACTIVATORS;

MUS;

EID: 61849093278     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddn428     Document Type: Article

References (63)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
2. Morales, L.M., Estevez, J., Suarez, H., Villalobos, R., Chacin de Bonilla, L. and Bonilla, E. (1989) Nutritional evaluation of Huntington disease patients. Am. J Clin. Nutr., 50, 145-150.
3. Trejo, A., Tarrats, R.M., Alonso, M.E., Boll, M.C., Ochoa, A. and Velasquez, L. (2004) Assessment of the nutrition status of patients with Huntington's disease. Nutrition, 20, 192-196.
4. Fatter, L.A. and Meaney, F.J. (1985) An anthropometric assessment of Huntington's disease patients and families. Am. J. Phys. Anthropol. 67, 185-194.
5. Sanberg, P.R., Fibiger, H.C. and Mark, R.F. (1981) Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med. J. Aust., 1, 407-409.
6. Myers, R.H., Sax, D.S., Koroshetz, W.J., Mastromauro, C., Cupples, L.A., Kiely, D.K., Pettengill, F.K. and Bird, E.D. (1991) Factors associated with slow progression in Huntington's disease. Arch. Neurol., 48, 800-804.
7. Stoy, N. and McKay, E. (2000) Weight loss in Huntington's disease. Ann. Neurol., 48, 130-131.
8. Djousse, L., Knowlton, B., Cupples, L.A., Marder, K., Shoulson, I. and Myers, R.H. (2002) Weight loss in early stage of Huntington's disease. Neurol., 59, 1325-1330.
9. Morton, G.J., Cummings, D.E., Baskin, D.G., Barsh, G.S. and Scwartz, M.W. (2006) Central nervous system control of food intake and body weight. Nature, 443, 289-295.
10. Petersen, A. and Bjorkqvist, M. (2006) Hypothalainic-endocrine aspects in Huntington's disease. Eur. J. Neurosci., 24, 961-967.
11. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
12. Fain, J.N., Del Mar,.N.A., Meade, C.A., Reiner, A. and Goldowitz, D. (2001) Abnormalities for the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. Hum. Mol. Genet., 10, 145-152.
13. Weydt, P., Pinedd, V.V., Torrence, A.E., Libby, R.T., Satterfield, T.F., Lazarowski, E.R., Gilbert, M.L., Morton, G.J., Bammler, T.K., Strand, A.D. et al. (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab., 4, 349-362.
14. Luthi-Carter, R., Hanson, S.A., Strand, A.D., Bergstrom, D.A., Chun, W., Peters, N.L., Woods, A.M., Chan, E.Y., Kooperberg, C., Krainc, D. et al. (2002) Dysregulation of gene expression in the R6/2 model of polyglutamine disease: Parallel changes in muscle and brain. Hum. Mol. Genet., 11, 1911-1126.
15. Strand, A.D., Aragaki, A.K., Shaw, D., Bird, T., Holton, J., Turner, C., Tapscott, S.J., Tabrizi, S.J., Schapira, A.H., Kooperberg, C. et al. (2005) Gene expression in Huntington's disease skeletal muscle: A potential biomarker. Hum. Mol. Genet., 14, 1863-1876.
16. Ribchester, R.R., Thomson, D., Wood, N.I., Hinks, T., GillingWater, T.H., Wishart, T.M., Court, F.A. and Morton, A.J. (2004) Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci., 20, 3092-3114.
17. Bjorkqvist, M., Fex, M., Renstrom, E., Wierup, N., Petersen, A., Gil, J., Bacos, K., Popovic, N., Li, J.Y., Sundler, F. et al. (2005) The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum. Mol. Genet., 14, 565-574.
18. Andreassen, O.A., Dedeoglu, A., Stanojevic, V., Hughes, D.B., Browne, S.E., Leech, C.A., Ferrante, R.J., Habener, J.F., Beal, M.F. and Thomas, M.K. (2002) Huntington's disease of the endocrine pancreas: Insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol. Dis., 11, 410-424.
19. Hurlbert, M.S., Zhou, W., Wasmeier, C., Kaddis, F.G., Hutton, J.C. and Freed, C.R. ([999) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes, 48, 649-651.
20. Goodman, A.O., Murgatroyd, P.R., Medina-Gomez, G., Wood, N.I., Finer, N., Vidal-Puig, A.J., Morton, A.J. and Barker, R.A. (2008) The metabolic profile of early Huntington's disease - a combined human and transgenic mouse study. Exp. Neurol., 210, 691-698.
21. van der Burg, J.M., Bacos, K., Wood, N.I., Lindqvist, A, Wierup, N., Woodman, B., Wamsteeker, J.I,, Smith, R., Deierborg, T., Kuhar, M.J. et al. (2008) Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis., 29, 41-51.
22. Chehab, F.F. (2008) Obesity and lipodystrophy - where do the circles intersect? Endocrinol., 149, 925-934.
23. Reue, K. and Phan, J. (2006) Metabolic consequences of lipodystrophy in mouse models. Curr. Opin. Clin. Nutr. Metabol. Care, 9, 436-441.
24. Josefsen, K., Nielsen, M.D., Jorgensen, K.H., Bock, T., Norremolle, A., Sorensen, S.A., Naver, B. and Hasholt, L. (2008) Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease. J. Neuroendocrinol., 20, 165-172.
25. Lalic, N.M., Marie, J., Svetel, M., Jotic, A., Stefanova, E., Lalic, K., Dragasevic, N., Milicic, T., Lukic, L. and Kostic, V.S. (2008) Glucose homeostasis in Huntington disease: Abnormalities in insulin sensitivity and early-phase insulin secretion. Arch. Neurol., 65, 476-480.
26. Ahinna, R.S. and Lazar, M.A. (2008) Adipokines and the peripheral and neural control of energy balance. Mol. Endocrinol. (Baltimore, Md. 22, 1023-1031.
27. Henry, B.A. and Clarke, I.J. (2008) Adipose tissue hormones and the regulation of food intake. J. Neuroendocrinol., 20, 842-849.
28. Scherer, P.E. (2006) Adipose tissue: From lipid storage compartment to endocrine organ. Diabetes, 55, 1537-1545.
29. Koebnick, C., Shaibi, G.Q., Kelly, L.A., Roberts, C.K., Lane, C.J., Toledo-Corral, C., Davis, J.N., Byrd-Williams, C., Weigensberg, M.J. and Goran, M. I. (2007) Leptin-to-adiponectin ratio as independent predictor of insulin sensitivity during growth in overweight Hispanic youth. J. Endocrinol. Invest., 30, RC13-RC16.
30. Norata, G.D., Raselli, S., Grigore, L., Garlaschelli, K., Dozio, E., Magni, P. and Catapano, A.L. (2007) Leptin:aDiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke, 38, 2844-2846.
31. Oda, N., Imamura, S., Fujita, T., Uchida, Y., Inagaki, K., Kakizawa, H., Hayakawa, N., Suzuki, A., Takeda, J., Horikawa, Y. et al. (2008) The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metab. Clin. Exptl., 57, 268-273.
32. Li, J.Y., Popovic, N. and Brundin, P. (2005) The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx, 2, 447-464.
33. Menalled, L.B., Sison, J.D., Dragatsis, L, Zeitlin, S. and Chesselet, M.F. (2003) Time course of varly motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol., 465, 11-26.
34. Hickey, M.A., Kosmalska, A., Enayati, J., Cohen, R., Zeitlin, S., Levine, M. and Chesselet, M.F. (2008) Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience, 157, 280-295.
35. Ahima, R.S. (2006) Adipose tissue as an endocrine organ. Obesity, 14 (Suppl. 5), 242S-249S.
36. Trujillo, M.E. and Scherer, P.E. (2006) Adipose tissue-derived factors: impact on health and disease. Endocrinol. Rev., 27, 762-778.
37. Berg, A.H. and Scherer, P.E. (2004) Adipose tissue, inflammation, and cardiovascular disease. Circ. Res., 96, 939-949.
38. Farmer, S.R. (2006) Transcriptional control of adipocyte formation. Cell Metab., 4, 263-273.
39. Rosen, E.D. and MacDougald, O.A. (2006) Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol., 7, 885-896.
40. Levine, M.S., Klapstein, G.J., Koppel, A., Gruen, E., Cepeda, C., Vargas, M.E., Jokel, E.S., Carpenter, E.M., Zanjani, H., Hurst, R.S. et al. (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res., 58, 515-532.
41. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N. and Krainc, D. (2006) Transcriptional repression of PGC-1 alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59-69.
42. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Jager, S., Handschin, C., Zheng, K., Lin, J., Yang, W. et al. (2006) Suppression of reactive oxygen species and nearodegeneration by the PGC-1 transcriptional coactivators. Cell, 127, 397-408.
43. Finck, B.N., Gropler, M.C., Chen, Z., Leone, T.C., Croce, M.A., Harris, T.E., Lawrence, J.C. Jr and Kelly, D.P. (2006) Lipin I is an inducible amplifier of the hepatic PGCT-1alpha/PPARalpha regulatory pathway. Cell Metab., 4, 199-210.
44. Lin, J., Handsehin, C. and Spiegelman, B.M. (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 11, 361-370.
45. Garg, A. (2004) Acquired and inherited lipodystrophies. N. Engl. J. Med., 350, 1220-1234.
46. Popovic, V., Svetel, M., Djurovic, M., Petrovic, S., Doknic, M., Pekic, S., Mitjic, D., Milic, N., Glodic, J., Dieguez, C. et al. (2004) Circulating and cerebrospinal fluid ghrelin and leptin: Potential role in altered body weight in Huntington's disease. Eur. J Endocrinol. 151, 451-455.
47. Sadri-Vakili, G. and Cha, J.H. (2006) Mechanisms of disease: Histone modifications in Huntington's disease. Nat. Clin. Pract. Neurol., 2, 330-338.
48. Cha, J.H. (2007) Transcriptional signatures in Huntington's disease. Prog. Neurobiol., 83, 228-248.
49. Hu, H., McCaw, E.A., Hebb, A.L., Gomez, G.T. and Denovan-Wright, E.M. (2004)Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur. J. Neurosci., 20, 3351-3363.
50. Luthi-Carter, R., Strand, A., Peters, N.L., Solano, S.M., Hollingsworth, Z.R., Menon, A.S., Frey, A.S,., Spektor, B.S., Penney, E.B., Schilling, G. et al. (2000) Dqcreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet., 9 1259-1271.
51. McCaw, E.A., Hu, H., Gomez, G.T., Hebb, A.L., Kelly, M.E. and Denovan-Wright, E.M. (2004) Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice Eur. J. Biochem., 271; 4909-4920.
52. Borovecki, F., Lovrecic, L., Zhou, J., Jeong, H., Then, F., Rosas, H.D., Hersch, S.M., Hogarth, P., Bouzou, B., Jensen, R.V. et al. (2005) Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl Acad. Sci., 102, 11023-11028.
53. Zhai, W., Jeong, H, Cui, L., Krainc, D. Ad Tjian, R. (2005) In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell, 123, 1241-1253.
54. Savas, J.N., Makusky, A., Ottosen, S., Baillat, D., Then, F., Krainc, D., Shiekhattar, R., Markey, S.P. and Tanese, N. (2008) Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. PNAS, 105, 10820-10825.
55. Leone, T.C., Lehman, J.J., Finck, B.N.,-Schaeffer, P.J., Wende, A.R., Boudina, S., Courtois, M., Wozniak, D.P., Sambandam, N., Bernal-Mizrachi, C. et al. (2005) PGC-1alpha deficiency causes multi-system energy metabolic derangements: Muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol., 3, e101.
56. Lin, J., Wu, P.H., Tarr, P.T., Lindenberg, K.S., St-Pierre, J., Zhang, C.Y., Mootha, V.K., Jager, S., Vianna, C.R., Reznick, R.M. et al. (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell, 119, 121-135.
57. Hickey, M.A., Gallant, K., Gross, G.G., Levine, M.S. and Chesselet, M.F. (2005) Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol. Dis., 20, 1-11.
58. Quintanilla, R.A., Jin, Y.N., Fuenzalida, K., Bronfman. M. and Johnson, G.V. (2008) Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin expressing cells: Possible role of PPARgamma in the pathogenesis of huntington disease. J. Biol. Chem., 283, 25628-25637.
59. Kjaci, M. (2008) Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res., 2008, 418765.
60. Phan, J., Peterly, M. and Reue, K. (2004) Lipin expression preceding peroxisome proliferator-activated receptor-gamma is critical for adipogenesis in vivo and in vitro. J. Bio. Chem., 279, 29558-29564.
61. Aiken, C.T., Tobin, A.J. and Schweitzer, E.S. (2004) A cell-based screen for drugs to treat Huntington's disease. Neurobiol. Dis., 16 546-555.
62. Addison, J.A. (1996) Safety testing of tebufenozide, a new molt-inducing insecticide, for effects on nontarget forest soil invertebrates. Ecotoxicol. Environ. Saf., 33, 55-61.
63. Kliewer, S.A., Umesono, K., Noonan, D.J., Heyman, R.A. and Evans, R.M. (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature, 358, 771-774.